MIDD

Dr. Daniel Röshammar Joins InSilicoTrials as Vice President of Research & Development

Retrieved on: 
Monday, February 12, 2024

MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.

Key Points: 
  • MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.
  • With an illustrious career spanning various therapeutic areas, including cardiovascular diseases, infectious diseases, reproductive health, and oncology, Dr. Röshammar's boasts significant expertise in clinical drug development, clinical pharmacology, and pharmacometrics.
  • "Daniel's appointment is a testament to our commitment to leading the way in AI and simulation tools for drug development," said Luca Emili, CEO of InSilicoTrials.
  • In his capacity as Vice President of Research & Development at InSilicoTrials, Dr. Daniel Röshammar will harness his profound knowledge in pharmacometrics and model-informed drug development to directly oversee and innovate our R&D projects.

Dr. Daniel Röshammar Joins InSilicoTrials as Vice President of Research & Development

Retrieved on: 
Monday, February 12, 2024

MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.

Key Points: 
  • MILAN, Feb. 12, 2024 /PRNewswire/ -- InSilicoTrials is thrilled to announce the appointment of Dr. Daniel Röshammar as Vice President of Research & Development, marking a significant step forward in our mission to revolutionize healthcare through the power of in silico technology.
  • With an illustrious career spanning various therapeutic areas, including cardiovascular diseases, infectious diseases, reproductive health, and oncology, Dr. Röshammar's boasts significant expertise in clinical drug development, clinical pharmacology, and pharmacometrics.
  • "Daniel's appointment is a testament to our commitment to leading the way in AI and simulation tools for drug development," said Luca Emili, CEO of InSilicoTrials.
  • In his capacity as Vice President of Research & Development at InSilicoTrials, Dr. Daniel Röshammar will harness his profound knowledge in pharmacometrics and model-informed drug development to directly oversee and innovate our R&D projects.

Middleby Acquires GBT GmbH Bakery Technology

Retrieved on: 
Wednesday, February 7, 2024

The Middleby Corporation (NASDAQ: MIDD) today announced the acquisition of GBT GmbH Bakery Technology (GBT).

Key Points: 
  • The Middleby Corporation (NASDAQ: MIDD) today announced the acquisition of GBT GmbH Bakery Technology (GBT).
  • “GBT customizable equipment highly complements our existing bakery brands and allows us to strengthen our European presence in large scale baking,” said Tim FitzGerald, CEO of Middleby.
  • “The company brings German engineering capabilities and a broad knowledge of full line bakery solution integration to Middleby.
  • The systems, products and services offered by GMT will enhance the capabilities of Middleby Bakery full line solutions.

Middleby Schedules Fourth Quarter Earnings Release and Conference Call

Retrieved on: 
Tuesday, February 6, 2024

The Middleby Corporation (NASDAQ: MIDD) will release 2023 fourth quarter earnings on Tuesday, February 20 before the market opens.

Key Points: 
  • The Middleby Corporation (NASDAQ: MIDD) will release 2023 fourth quarter earnings on Tuesday, February 20 before the market opens.
  • The company has scheduled a conference call to discuss the results at 11 a.m. Eastern/10 a.m. Central Time on February 20.
  • The conference call is accessible through the Investor Relations section of the company website at www.middleby.com .
  • If website access is not available, attendees can join the conference by dialing (833) 630-1956, or for international access use (412) 317-1837.

Middleby Appoints Stephen Scherger and Tejas Shah to its Board of Directors

Retrieved on: 
Tuesday, January 16, 2024

The Middleby Corporation (NASDAQ: MIDD) today announced the expansion of its Board of Directors with the appointment of Stephen Scherger and Tejas Shah.

Key Points: 
  • The Middleby Corporation (NASDAQ: MIDD) today announced the expansion of its Board of Directors with the appointment of Stephen Scherger and Tejas Shah.
  • “Steve and Tejas bring deep experience to the Middleby Board, expanding our proficiencies in risk management, cybersecurity, innovation, acquisitions and ESG matters,” said Tim FitzGerald, Middleby CEO.
  • “Adding their perspectives to the Middleby Board will greatly enhance our ability to strategically grow and expand our business.
  • The distinct expertise and knowledge that both Steve and Tejas bring to Middleby will benefit our employees, customers, and shareholders,” said Gordon O’Brien, Middleby Board Chairman.

PumasAI Maintains Strong Growth Trajectory with New Product Engineering and Pharmacometrics Hires from JuliaHub and Pfizer

Retrieved on: 
Friday, January 12, 2024

DOVER, Del., Jan. 12, 2024 /PRNewswire-PRWeb/ -- PumasAI, a pioneering organization at the forefront of transforming data into life-saving decisions with remarkable speed, is proud to announce the appointment of two distinguished leaders to its team.

Key Points: 
  • Dr. Andreas Noack, a luminary in product engineering, joins PumasAI as the Head of Product Engineering, and Dr. Jessica Wojciechowski, an esteemed expert in clinical pharmacology and pharmacometrics, will be joining the team as the Director of Clinical Pharmacology and Pharmacometrics.
  • - Dr. Vijay Ivaturi, CEO, PumasAI
    Dr. Andreas Noack, a luminary in product engineering, joins PumasAI as the Head of Product Engineering.
  • Dr. Jessica Wojciechowski, an esteemed expert in clinical pharmacology and pharmacometrics, will be joining the team as the Director of Clinical Pharmacology and Pharmacometrics.
  • Based in Connecticut, Dr. Wojciechowski transitions to PumasAI from Pfizer, where she held the pivotal role of Director of Pharmacometrics.

Middleby Schedules Third Quarter Earnings Release and Conference Call

Retrieved on: 
Monday, October 30, 2023

The Middleby Corporation (NASDAQ: MIDD) will release 2023 third quarter earnings on Wednesday, November 8 before the market opens.

Key Points: 
  • The Middleby Corporation (NASDAQ: MIDD) will release 2023 third quarter earnings on Wednesday, November 8 before the market opens.
  • The company has scheduled a conference call to discuss the results at 11 a.m. Eastern/10 a.m. Central Time on November 8.
  • The conference call is accessible through the Investor Relations section of the company website at www.middleby.com .
  • If website access is not available, attendees can join the conference by dialing (833) 630-1956 or for international access use (412) 317-1837.

Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1

Retrieved on: 
Wednesday, November 1, 2023

Sonlicromanol works in three distinct ways by modulating oxidative and reductive distress, along with anti-inflammatory properties.

Key Points: 
  • Sonlicromanol works in three distinct ways by modulating oxidative and reductive distress, along with anti-inflammatory properties.
  • The compound is currently under investigation for its effectiveness in treating adult patients diagnosed with primary mitochondrial disease due to the m.3243A>G mutation in their mitochondrial DNA.
  • This mutation is linked to various conditions such as classical MELAS and MIDD syndromes, CPEO, and mixed phenotypes.
  • These findings suggest a wider range of potential applications for sonlicromanol beyond its initial focus on primary mitochondrial diseases.

Khondrion announces grant of patents in the US and Europe for its lead candidate sonlicromanol, covering the anti-inflammatory effect on mPGES-1

Retrieved on: 
Wednesday, November 1, 2023

Sonlicromanol works in three distinct ways by modulating oxidative and reductive distress, along with anti-inflammatory properties.

Key Points: 
  • Sonlicromanol works in three distinct ways by modulating oxidative and reductive distress, along with anti-inflammatory properties.
  • The compound is currently under investigation for its effectiveness in treating adult patients diagnosed with primary mitochondrial disease due to the m.3243A>G mutation in their mitochondrial DNA.
  • This mutation is linked to various conditions such as classical MELAS and MIDD syndromes, CPEO, and mixed phenotypes.
  • These findings suggest a wider range of potential applications for sonlicromanol beyond its initial focus on primary mitochondrial diseases.

Mark Lovern Joins InSilicoTrials as Chief Platform Officer

Retrieved on: 
Tuesday, October 17, 2023

MILAN, Oct. 17, 2023 /PRNewswire/ -- Today, InSilicoTrials warmly welcomes Dr. Mark Lovern in his new role as Chief Platform Officer, a move marking the company's continued commitment to leading the frontier of AI-driven innovation and simulation in life sciences.

Key Points: 
  • MILAN, Oct. 17, 2023 /PRNewswire/ -- Today, InSilicoTrials warmly welcomes Dr. Mark Lovern in his new role as Chief Platform Officer, a move marking the company's continued commitment to leading the frontier of AI-driven innovation and simulation in life sciences.
  • With the digital transformation revolution reshaping various industries, the role of Chief Platform Officer becomes even more pivotal.
  • Dr. Mark Lovern brings in a rich history, having 25+ years of experience in the application of model-informed drug development (MIDD).
  • Before joining InSilicoTrials as Chief Platform Officer, he had gathered extensive experience in both consultancy (Certara) and biopharma companies (GSK and UCB), contributing significantly to the field of quantitative pharmacology.